Expression of LRIG1 is associated with good prognosis and human papillomavirus status in oropharyngeal cancer
2014 (English)In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 110, 1793-1800 p.Article in journal (Refereed) Published
Background:The incidence of human papillomavirus (HPV)-associated oropharyngeal cancer has increased rapidly during the past decades. HPV is typically associated with a favourable outcome; however, a need exists for new and more effective prognostic and predictive markers for this disease. Leucine-rich repeats and immunoglobulin-like domains (LRIG)-1 is a tumour suppressor protein that belongs to the LRIG family. LRIG1 expression has prognostic significance in various human cancers, including cervical cancer, where HPV is a key aetiological agent.Methods:The prognostic value of LRIG1 and LRIG2 immunoreactivity was investigated in tumour specimens from a Swedish cohort of patients with tonsillar and base of tongue oropharyngeal cancers, including 278 patients.Results:LRIG1 immunoreactivity correlated with disease-free survival and overall survival in univariate and multivariate analyses. Notably, patients with HPV-positive tumours with high LRIG1 staining intensity or a high percentage of LRIG1-positive cells showed a very good prognosis. Furthermore, LRIG1 expression correlated with HPV status, whereas LRIG2 expression inversely correlated with HPV status.Conclusions:Taken together, the results suggest that LRIG1 immunoreactivity could be a clinically important prognostic marker in HPV-associated oropharyngeal cancer.
Place, publisher, year, edition, pages
Nature Publishing Group, 2014. Vol. 110, 1793-1800 p.
LRIG1, CD44, HPV, p16
Cancer and Oncology
Research subject Oncology
IdentifiersURN: urn:nbn:se:umu:diva-86392DOI: 10.1038/bjc.2014.87PubMedID: 24548859OAI: oai:DiVA.org:umu-86392DiVA: diva2:698754